Postpartum Depression (PPD): Market View, Current and Future Competitive Landscape
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
The postpartum depression market is evolving as established antidepressant treatments compete with faster-acting therapies and a developing pipeline of novel approaches.
GlobalData’s Postpartum Depression (PPD): Market View, Current and Future Competitive Landscape provides a data-driven assessment of the PPD therapeutics market, combining epidemiology, treatment analysis, marketed products, pipeline intelligence, clinical trials, deal activity and commercial assessment.
In 2025, there were 10.89 million prevalent cases of PPD across the 16 countries covered in GlobalData’s epidemiology forecast.
The PPD pipeline comprises 15 molecules, including two in Phase III and seven in Phase II, while no assets were in the pre-registration stage.
The report examines the current treatment environment alongside the future competitive landscape, helping pharmaceutical companies, investors and commercial teams understand where opportunities and competitive pressures are emerging.
What is the outlook for the postpartum depression market?
The postpartum depression therapeutics market is undergoing a period of therapeutic evolution.
PPD is commonly managed with psychotherapy and antidepressants, particularly SSRIs, with treatment decisions influenced by breastfeeding considerations and patient preferences.
For moderate-to-severe disease, faster-acting neuroactive steroid treatments such as IV brexanolone and oral zuranolone provide alternative approaches.
The emerging pipeline adds another layer to the competitive landscape, with 15 molecules currently identified across development stages.
Understanding how marketed therapies, pipeline assets and future market catalysts interact is therefore important for companies assessing the PPD market.
How prevalent is postpartum depression?
GlobalData’s epidemiology forecast identifies 10.89 million prevalent PPD cases in 2025 across 16 countries.
This patient population provides an important foundation for assessing the potential market for existing and emerging treatments.
However, prevalence alone does not determine commercial opportunity. Treatment patterns, therapy preferences, disease severity, access, pricing and reimbursement can all influence the uptake and commercial performance of individual therapies.
The report therefore combines epidemiological analysis with treatment, marketed-product and commercial assessments.
PPD Market Size, Competitive Landscape and Treatment Trends
PPD is commonly managed with psychotherapy and antidepressants, particularly SSRIs. Treatment decisions can also consider breastfeeding, patient preferences, and practical support needs.
For moderate-to-severe disease, neuroactive steroid treatments offer additional options. These include IV brexanolone and oral zuranolone.
However, access, cost, sedation, and treatment logistics may influence uptake. For severe or high-risk cases, urgent psychiatric assessment may be required.
The report helps you understand how these treatment approaches fit within the broader competitive landscape. It also provides insight into marketed products, mechanisms of action, molecule types, pricing, reimbursement, and sales forecasts.
PPD Drug Pipeline Analysis and Emerging Therapeutics
The PPD pipeline includes 15 molecules. There are currently no assets in the pre-registration stage.
Two molecules are in Phase III development. Seven are in Phase II development.
This pipeline view can help you assess where innovation is concentrated. Moreover, it can support comparisons across development stage, mechanism of action, molecule type, and route of administration.
The report also includes product profiles and sales forecasts. In addition, it provides drug-specific and indication-specific probability of technical and regulatory success (PTSR) and likelihood of approval (LoA) analysis.
As a result, you can better evaluate potential opportunities and development risks.
PPD Clinical Trials Analysis: Sponsors, Phases, Sites and Enrollment
Clinical development activity provides another lens on market momentum.
Over the past decade, 159 clinical trials have been conducted in PPD. The highest number of studies was initiated in 2024, with 24 trials. This was followed by 2021, with 23 trials.
The report also identifies 2022 as the year with the most Phase III trial initiations, with five studies.
You can assess clinical activity by:
- Trial phase and status
- Sponsors
- Geography
- Endpoint status
- Enrollment
- Trial sites
- Virtual trial components
- Biomarkers
- Race and ethnicity
- Single-country and multinational studies
In addition, feasibility analysis provides geographic and benchmark perspectives. This can help support clinical development planning and site strategy.
PPD Pricing, Reimbursement and Annual Therapy Cost Analysis
Commercial potential depends on more than clinical development.
The report examines pricing and reimbursement considerations for PPD therapies. It also assesses annual therapy costs, time to pricing, and time to reimbursement.
This can help you understand potential commercial considerations across marketed and pipeline products.
Therefore, the analysis can support market access planning and commercial strategy alongside pipeline evaluation.
PPD Deals, M&A and Licensing Landscape
Capital and strategic activity provide important signals about competitive positioning.
Over the past decade, acquisitions represented the largest share of PPD-related deals in North America, accounting for 44.4%.
In Europe, licensing agreements were most prevalent, representing 40% of deals. In Asia-Pacific, partnerships accounted for 50%.
South America, along with the Middle East and Africa, recorded only asset transactions in the period covered, accounting for 100% of deals.
The report reviews mergers, acquisitions, and strategic alliances by region. It also provides an overview of recent deals.
You can use these insights to inform in-licensing and out-licensing strategies. They may also help you identify companies and technologies that warrant closer evaluation.
Scope
The report provides comprehensive analysis across:
- Disease landscape: disease overview, epidemiology, and treatment
- Marketed drugs: leading products, approval status, drug type, mechanism of action, and sales forecasts
- Pricing and reimbursement: annual therapy cost, pricing, and reimbursement considerations
- Pipeline drugs: development stage, mechanism of action, route of administration, sales forecasts, PTSR, and LoA
- Clinical trials: phases, status, sponsors, geography, endpoints, enrollment, sites, biomarkers, and feasibility
- Deals: M&A, licensing, and strategic alliances by region
- Commercial assessment: key market players and competitive considerations
- Future market catalysts: factors that may influence the market ahead
PPD Market Outlook: Understand What Could Shape the Future
The PPD therapeutics landscape continues to develop across treatment, clinical research, and commercial activity.
The pipeline includes assets across multiple development stages. At the same time, clinical trial activity and strategic transactions provide additional signals about market direction.
The report’s future market catalysts section helps you consider factors that may influence the market ahead.
If PPD is relevant to your portfolio, pipeline, or commercial strategy, this analysis can help you evaluate the landscape now and prepare for potential changes ahead.
Who Should Buy This PPD Competitive Landscape Report?
This report is particularly relevant for:
- Pharmaceutical companies
- Biotechnology companies
- Heads of strategy and corporate development
- Business development and licensing teams
- R&D and pipeline strategy leaders
- Clinical development teams
- Commercial strategy teams
- Market access and pricing teams
- Competitive intelligence teams
- Sales and marketing leaders
- Healthcare investors and analysts
If you are evaluating PPD assets, competitors, partnerships, or market opportunities, this report can provide relevant intelligence for your next decision.
Key Highlights
Reasons to Buy
Understanding competitors is central to commercial decision-making.
The report assesses key market players and their positioning across the PPD therapeutics landscape. It also reviews marketed products, pipeline assets, sales forecasts, and development activity.
You can use the analysis to identify emerging players with potentially strong portfolios. Moreover, it can help you assess potential competitive threats and develop appropriate counter-strategies.
How Companies Can Use This PPD Market Report
This report is designed to support practical commercial and strategic decisions.
- Pharmaceutical and biotech companies can use it to evaluate competitors, assess pipeline opportunities, and shape portfolio strategy.
- Business development and licensing teams can use pipeline and deals intelligence to identify potential partners and assess in-licensing or out-licensing opportunities.
- Commercial strategy teams can assess market trends, marketed products, sales forecasts, pricing, and reimbursement considerations.
- Clinical development teams can use trial, sponsor, enrollment, site, and feasibility data to support development planning.
- Market access teams can examine pricing, reimbursement, and annual therapy cost considerations.
- Investors and corporate strategy teams can use pipeline, competitive, clinical, and deals intelligence to assess potential market opportunities.
PPD Market Report Value Proposition: Turn Market Intelligence Into Better Decisions
This report goes beyond a snapshot of the PPD market.
It brings together disease, epidemiology, treatment, marketed product, pipeline, clinical trial, pricing, reimbursement, deals, and commercial intelligence.
Therefore, you can assess the market from multiple decision-making angles within one research framework.
The report may help you:
- Identify emerging PPD therapeutic opportunities
- Evaluate competitors and pipeline strength
- Compare marketed and pipeline products
- Assess potential licensing and partnership targets
- Understand clinical development activity
- Evaluate pricing and reimbursement considerations
- Support sales and marketing strategy
- Identify areas for investment and consolidation
- Monitor future market catalysts
- Develop more informed competitive strategies
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Postpartum Depression (PPD): Market View, Current and Future Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
